Search Results
Michael J Reardon, MD - TAVR in Asymptomatic or Moderate AS
TAVR-Device Selection & Expanding Indications/Percutaneous Alt. Access (Michael J. Reardon, MD)
Which Low-Risk Patients Should Receive TAVR?
TAVR Horizons: Partner II, SurTAVI and Beyond (Michael J. Reardon, MD) April 30, 2016
CVI2018 Session: Is there a problem with undertreatment with AVR? - Michael Reardon, MD
SESSION SIX • Q & A: Audience Response and Panel Discussion (LITTLE, MD/REARDON, MD)
Lifetime Management of Aortic Stenosis (Kendra J. Grubb, MD, Michael Reardon, MD)
Bicuspid Valve Aortopathy: Surgical and Medical Considerations (Michael J. Reardon, MD)
Disruptive Innovation: TAVR 20 Years Later | April 4
Summer Series: SAVR vs. TAVR: Controversial Cases and Insights from the Experts
Transcatheter Aortic Valve Replacement: Will Surgical AVR Disappear? (Michael Reardon, MD)
CVI2018 Session: Science and Needs for Aortic Valve Therapy
